Volume 27, Number 8—August 2021
Letter
Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
Table
Serotypes | Cases of invasive pneumococcal disease, no. (%) |
|
---|---|---|
Israel | France | |
Total |
216 (100.0) |
113 (100.0) |
PCV13 serotypes | 22 (10.2) | 5 (4.4) |
22F | 8 (3.7) | 8 (7.1) |
33F |
23 (10.6) |
5 (4.4) |
PCV15 serotypes† | 53 (24.5) | 18 (15.9) |
8 | 2 (0.9) | 2 (1.8) |
10A | 8 (3.7) | 11 (9.7) |
11A | 3 (1.4) | 2 (1.8) |
12F | 58 (26.9) | 1 (0.9) |
15B/C |
10 (4.6) |
13 (11.5) |
PCV20 serotypes‡ |
134 (62.0) |
47 (41.6) |
Non-VT20 | 82 (38.0) | 66 (58.4) |
24F |
7 (3.2) |
31 (27.4) |
VT20–13 |
112 (51.9) |
42 (37.2) |
Non-PCV13 | 194 (89.8) | 108 (95.6) |
*Non-VT20, serotypes in PCV20; PCV13, 13-valent PCV; PCV15, 15-valent PCV; PCV20, 20-valent PCV; PCV, pneumococcal conjugate vaccine; VT20–13, vaccine types in PCV20 but not PCV13. †Comprises PCV13 serotypes as well as 22F and 33F. ‡Comprises PCV15 serotypes as well as 8, 10A, 11A, 12F, and 15B/C.
Page created: May 17, 2021
Page updated: July 19, 2021
Page reviewed: July 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.